Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Posted: November 12, 2024 at 2:47 am
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).
Read more from the original source:
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Posted in Global News Feed
Comments Off on Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Posted: November 12, 2024 at 2:47 am
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million
Read more from the original source:
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Posted in Global News Feed
Comments Off on 23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
Posted: November 12, 2024 at 2:47 am
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.
Read the rest here:
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
Posted in Global News Feed
Comments Off on MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
Posted: November 12, 2024 at 2:47 am
Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program.
Posted in Global News Feed
Comments Off on Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Posted: November 12, 2024 at 2:47 am
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2024, and provided a general business update.
Read this article:
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Posted in Global News Feed
Comments Off on Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Posted: November 12, 2024 at 2:47 am
Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.
Continue reading here:
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Posted in Global News Feed
Comments Off on Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
Posted: November 12, 2024 at 2:47 am
PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024.
Follow this link:
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
Posted in Global News Feed
Comments Off on NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Posted: October 30, 2024 at 2:42 am
Ad hoc announcement pursuant to Art. 53 LR
See the article here:
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Posted in Global News Feed
Comments Off on Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
Posted: October 30, 2024 at 2:42 am
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -
Posted in Global News Feed
Comments Off on Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
